Last reviewed · How we verify
CORDYCEPIN
At a glance
| Generic name | CORDYCEPIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma (PHASE1,PHASE2)
- Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors (PHASE2)
- PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0) (PHASE2)
- Immune Modulation With PRaG-1 Treatment (PHASE2)
- Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia (PHASE1)
- Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CORDYCEPIN CI brief — competitive landscape report
- CORDYCEPIN updates RSS · CI watch RSS